gerry: an exceptionally interesting find, well delved!
"The licensed technology utilizes small molecule aptamers for regulating gene expression in vivo, results of which were previously published in Science. Oxford BioMedica plans to incorporate the aptamer-based technology into its platform of gene therapy products and delivery systems for the treatment of cancer and neurodegenerative diseases."
As you may remember a few weeks ago I mentioned, I think in discussion with terry ward, that I had some concern about how dopamine production by ProSavin would be regulated - ie would the body be able to regulate how much was produced. If not, too much of a good thing could prove a very bad thing. I don't know the answer but it may be that OXB think that some regulatory mechanism does need to be incorporated and that could be what this is about. (I know nothing about the particular technology involved but I'm sure OXB have done their homework!) It could be nothing to do with ProSavin of course, but is potentially of course very useful in any application of gene therapy where you need to be able to turn up or down the amount of gene product being produced. So, very glad OXB have this available (and as an exclusive licence), a very positive move indeed.
Oxford Biomed stock quotes
Oxford Biomed stock charts
Follow this thread
